Keros Therapeutics, Inc. Preferred Stock, Par or Stated Value Per Share
Keros Therapeutics, Inc. (KROS) had Preferred Stock, Par or Stated Value Per Share of $0.00 per share as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockParOrStatedValuePerShare · last filed 2026-08-03
- 2026-06-30: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2026-03-31: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2025-12-31: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2025-09-30: Preferred Stock, Par or Stated Value Per Share $0.00.
| Period end | Preferred Stock, Par or Stated Value Per Share |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-03 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-03 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 |
| 2025-04-09 | $0.00 10-Q · filed 2026-08-03 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-04 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-26 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |